Build status - In Progress

I5T-MC-AACI Assessment of Safety Tolerability and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease Phase II

Recruiting
99 years or below
All
1 Location

Brief description of study

This protocol is an 18-month, multicenter, randomized, double-blind, placebo-controlled, phase 2 study comparing 1400 mg of donanemab versus placebo over 76 weeks in approximately 500 patients with early symptomatic AD. Study duration including screening and post treatment is up to 133 weeks. Study drug will be prepared and stored at IDS.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 08 Feb 2023. Study ID: 848402

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center